← Back to Clinical Trials
Recruiting NCT06591286

Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control

Trial Parameters

Condition Diabetes Mellitus, Type 2
Sponsor Shanghai 6th People's Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2024-10-25
Completion 2026-03-10
Interventions
RT-CGMSMBG

Brief Summary

Glucose monitoring is an important part of self-management for patients with diabetes. The results of glucose monitoring not only help to assess the degree of glucose metabolism disorders in patients, but also help physicians to make clinical decisions and guide patients in self-management. Despite extensive efforts and advances in diabetes management during hospitalization, glucose control after patients is discharged home remains a challenge. This trial aims to explore the effect of real-time continuous glucose monitoring (RT-CGM) system compared to self-monitoring of blood glucose (SMBG) group on glucose and self-efficacy of type 2 diabetes patients treated with insulin after discharge from the hospital.

Eligibility Criteria

Inclusion Criteria: 1. 18 years old ≤ age ≤ 80 years old. 2. Type 2 diabetes admitted to Department of Endocrinology and Metabolism. 3. 8% ≤ HbA1c ≤ 12% in the last 1 month. 4. Insulin therapy within 1 month of planned discharge from hospital. 5. Frequency of self-monitoring of blood glucose \<4 times per week and no use of real-time continuous glucose monitoring system in the 3 months prior to hospitalisation. 6. Willing and able to provide written informed consent and comply with the requirements of this study. Exclusion Criteria: 1. Oral steroid hormone therapy. 2. Patients with acute complications of diabetes (including Diabetic ketoacidosis, hyperglycemia and hyperosmolality, Lactic acidosis) 3. Patients with severe liver disease (alanine aminotransferase or glutamine aminotransferase exceeding more than three times the upper limit of normal). 4. Patients with severe kidney injury or end-stage renal disease (eGFR \< 30 mL/min/1.73 m2). 5. Participants were unable to tolerate tape

Related Trials